Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis

References

• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.
   PubMed Web of Science ®Google Scholar
• Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057–66.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897–907.
   PubMed Web of Science ®Google Scholar
• Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 1989;79:1374–87.
   Google Scholar
• Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22:1769–76.
   PubMed Web of Science ®Google Scholar
• Khouzam RN, Shaheen M, Aziz RK, Ibebuogu UN. The important role of inflammatory biomarkers pre and post bare–metal and drug–eluting stent implantation. Can J Cardiol. 2012;28:700–5.
   PubMed Web of Science ®Google Scholar
• Dotsenko O, Chaturvedi N, Thom S, Wright A, Mayet J, Shore A, et al. Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J Thromb Haemost. 2007;5:2036–42.
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, et al. Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial). Am J Cardiol. 2007;99:1055–61.
   PubMed Web of Science ®Google Scholar
• Ommen SR, Gibbons RJ, Hodge DO, Thomson SP. Usefulness of the lymphocyte concentration as a prognostic marker in coronary artery disease. Am J Cardiol. 1997;79:812–4.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. Catheter Cardiovas Interv. 2012;79:453–95.
   PubMed Web of Science ®Google Scholar
• Smith Jr S, Dove JT, Jacobs A. Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty: ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PCI guidelines): executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 2001;37:2215–38.
   PubMed Web of Science ®Google Scholar
• Niccoli G, Montone RA, Ferrante G, Crea F. The evolving role of inflammatory biomarkers in risk assessment after stent implantation. J Am Coll Cardiol. 2010;56:1783–93.
   PubMed Web of Science ®Google Scholar
• Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol. 2011;9:53–62.
   PubMed Web of Science ®Google Scholar
• Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, et al. Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med. 2008;9:156–65.
   PubMedGoogle Scholar
• Pietersma A, Kofflard M, de Wit LE, Stijnen T, Koster JF, Serruys PW, et al. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91:1320–5.
   PubMed Web of Science ®Google Scholar
• Turak O, Ozcan F, Isleyen A, Tok D, Sokmen E, Buyukkaya E, et al. Usefulness of the neutrophil-to-lymphocyte ratio to predict bare-metal stent restenosis. Am J Cardiol. 2012;110:1405–10.
   PubMed Web of Science ®Google Scholar
• Rahel BM, Visseren FL, Suttorp MJ, Plokker TH, Kelder JC, de Jongh BM, et al. Preprocedural serum levels of acute-phase reactants and prognosis after percutaneous coronary intervention. Cardiovasc Res. 2003;60:136–40.
   PubMed Web of Science ®Google Scholar
• Türker S, Güneri S, Akdeniz B, Özcan MA, Baris N, Badak Ö, et al. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol. 2006;97:198–202.
   PubMed Web of Science ®Google Scholar
• Iijima R, Byrne RA, Ndrepepa G, Braun S, Mehilli J, Berger PB, et al. Pre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trials. Heart. 2009;95:107–12.
   PubMed Web of Science ®Google Scholar
• Vidwan P, Lee S, Rossi JS, Stouffer GA. Relation of platelet count to bleeding and vascular complications in patients undergoing coronary angiography. Am J Cardiol. 2010;105:1219–22.
   PubMed Web of Science ®Google Scholar
• Zouridakis EG, Garcia-Moll X, Kaski JC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol. 2000;86:449–51.
   PubMed Web of Science ®Google Scholar
• Kurtul A, Murat SN, Yarlioglues M, Duran M, Ergun G, Acikgoz SK, et al. Association of latelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol. 2014;114:972–8
   PubMed Web of Science ®Google Scholar
• Açar G, Kalkan ME, Avci A, Alizade E, Tabakci MM, Toprak C, et al. The relation of platelet–lymphocyte ratio and coronary collateral circulation in patients with stable angina pectoris and chronic total occlusion. Clin Appl ThrombHemost. 2013:1076029613508599.
   Google Scholar
• Kurtul A, Yarlioglues M, Murat SN, Ergun G, Duran M, Kasapkara HA, et al. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow following primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114:342–7
   PubMed Web of Science ®Google Scholar
• Sunbul M, Gerin F, Durmus E, Kivrak T, Sari I, Tigen K, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. Clin Exp Hypertens. 2013;36:1–5.
   PubMed Web of Science ®Google Scholar
• Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlich H, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One. 2013;8:e67688.
   PubMed Web of Science ®Google Scholar
• Temiz A, Gazi E, Güngör Ö, Barutçu A, Altun B, Bekler A, et al. Platelet/lymphocyte ratio and risk of in-hospital mortality in patients with ST-elevated myocardial infarction. Med Sci Monit. 2014;20:660–5.
   PubMed Web of Science ®Google Scholar
• Azab B, Shah N, Akerman M, McGinn JT Jr. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34:326–34.
   PubMed Web of Science ®Google Scholar